Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

Trial Profile

Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Cancer; Chronic myeloid leukaemia; Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 17 Jul 2017 Planned End Date changed from 30 Dec 2018 to 28 Feb 2018.
    • 17 Jul 2017 Planned primary completion date changed from 30 Dec 2018 to 27 Feb 2018.
    • 08 Nov 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top